Antidiabetics Market

• In December 2019, Mankind Pharmaceuticals signed collaborative marketing agreement with Glenmark Pharmaceuticals to market remoglifozin, an antidiabetic drug, in India. This has allowed both the firms to expand their business in Asia Pacific region.

• In February 2018, Cipla collaborated with Novartis and Johnson & Johnson to market their anti-diabetics drugs. This collaboration has led to business expansion of the firm thereby strengthening its market position.

In the report, The Antidiabetics Market has been segmented by Product, Drug Class, Type, Administration Route and Geography.

Antidiabetics Market, Segmentation by Product

The Antidiabetics Market has been segmented by Product into Insulin - Rapid Acting Analog, Long Acting Analog, Premixed Insulin, Short Acting Analog and Intermediate Acting Analog, Drug Class - Alpha Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon Like Peptide) Agonists, DPP-Iv (Dipeptidyl Peptidase) Inhibitors, Meglitinides, SGLT-Ii (Sodium Glucose Transport Proteins) Inhibitors and Thiazolidinedione.

Rapid Acting Analog
Rapid acting insulin analogs are used to manage blood sugar spikes immediately after meals. They provide fast onset and short duration of action, enhancing postprandial control. This segment contributes approximately 14% to the overall insulin market due to its effectiveness in intensive insulin therapy.

Long Acting Analog
Long acting analogs offer stable, 24-hour blood glucose control, minimizing the risk of nocturnal hypoglycemia. Their convenience and reliability make them a preferred choice for basal insulin therapy, accounting for around 22% of the insulin segment.

Premixed Insulin
Premixed insulin combines both rapid and intermediate-acting components to simplify dosing schedules. Popular among elderly and type 2 diabetes patients, this category holds nearly 18% of the insulin market share.

Short Acting Analog
Short acting analogs, often referred to as regular insulin, are primarily used before meals. Despite newer alternatives, they still contribute about 10% of the insulin market, especially in regions with limited access to analog formulations.

Intermediate Acting Analog
Intermediate acting insulin, like NPH, provides basal coverage for 12–18 hours. Though gradually replaced by newer long-acting analogs, it still occupies around 8% of the insulin market, especially in low-income economies.

Alpha Glucosidase Inhibitors
Alpha glucosidase inhibitors delay carbohydrate absorption in the intestine, helping reduce post-meal blood sugar spikes. They hold a modest share of about 4%, primarily used in combination therapies for type 2 diabetes.

Biguanides
Biguanides, particularly metformin, are first-line therapies in type 2 diabetes management. Known for their efficacy, low cost, and cardiovascular benefits, they dominate the market with over 30% share among oral antidiabetics.

Sulphonylureas
Sulphonylureas stimulate insulin secretion and are widely used in early-stage type 2 diabetes. Despite the risk of hypoglycemia, they retain about 12% market share due to affordability and physician familiarity.

GLP-1 (Glucagon Like Peptide) Agonists
GLP-1 agonists mimic natural incretin hormones, promoting insulin secretion and supporting weight loss. They are gaining rapid popularity and hold around 10% market share, driven by both efficacy and cardiovascular safety.

DPP-IV (Dipeptidyl Peptidase) Inhibitors
DPP-IV inhibitors enhance endogenous incretin levels, aiding glucose-dependent insulin release. This class accounts for nearly 9% of the oral antidiabetic drug market, favored for its low side-effect profile.

Meglitinides
Meglitinides act on pancreatic beta cells to increase insulin secretion in a short duration. Used primarily for postprandial glucose control, they hold a minor share of about 3% due to limited long-term data and the availability of better alternatives.

SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
SGLT-II inhibitors work by preventing glucose reabsorption in the kidneys, promoting its excretion through urine. They hold approximately 11% of the market and are increasingly used due to added benefits in heart and kidney health.

Thiazolidinedione
Thiazolidinediones improve insulin sensitivity by acting on PPAR-gamma receptors. Although concerns over side effects have limited their use, they still contribute around 2% to the antidiabetics market.

Antidiabetics Market, Segmentation by Drug Class

The Antidiabetics Market has been segmented by Drug Class into GLP-1 Receptor Agonists and Insulin.

GLP-1 Receptor Agonists
GLP-1 receptor agonists help regulate blood glucose by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. These drugs are highly preferred due to their cardiovascular benefits and ability to support weight loss. This segment currently holds about 28% of the global antidiabetics market and continues to grow rapidly with increasing adoption in type 2 diabetes therapy.

Insulin
Insulin remains the cornerstone for managing both type 1 and advanced type 2 diabetes. Available in multiple forms like rapid-acting, long-acting, and premixed formulations, it supports personalized glucose control strategies. Insulin accounts for approximately 45% of the antidiabetics market, driven by its necessity in chronic disease management and advances in delivery technologies.

Antidiabetics Market, Segmentation by Type

The Antidiabetics Market has been segmented by Type into Type 1 and Type 2.

Type 1
Type 1 diabetes accounts for approximately 10–12% of the global diabetic population and is characterized by autoimmune destruction of pancreatic beta cells. Patients require lifelong insulin therapy starting at diagnosis. The demand for continuous glucose monitoring and advanced insulin delivery devices is growing significantly in this segment.

Type 2
Type 2 diabetes dominates the antidiabetics market, contributing to nearly 88–90% of the total cases worldwide. It is associated with insulin resistance and is largely driven by obesity, aging, and sedentary lifestyles. This segment shows strong uptake of both oral antidiabetic drugs and injectables, including GLP-1 receptor agonists and SGLT-2 inhibitors.

Antidiabetics Market, Segmentation by Administration Route

The Antidiabetics Market has been segmented by Administration Route into Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral and Others.

Insulin Syringe/ Insulin Pen
Insulin syringes and pens remain the most commonly used routes of insulin delivery, accounting for nearly 48% of the administration segment. They offer ease of use, cost-effectiveness, and wide availability. Pens, in particular, are gaining popularity for their accurate dosing and patient-friendly design.

Insulin Pump
Insulin pumps provide continuous subcutaneous insulin infusion and are favored for tight glycemic control in Type 1 diabetes patients. Representing about 12% of the market, their adoption is driven by technological innovations like smart pumps and integration with CGM systems.

Intravenous Infusion
Intravenous insulin administration is typically used in hospital settings for managing hyperglycemia emergencies such as diabetic ketoacidosis. Although it holds a smaller market share of around 5%, it plays a critical role in inpatient care.

Oral
The oral route dominates the antidiabetics market with over 30% share, led by drug classes like biguanides, DPP-IV inhibitors, SGLT2 inhibitors, and sulphonylureas. Oral medications are the preferred first-line therapy for most Type 2 diabetes patients due to ease of administration and patient compliance.

Others
The ‘Others’ segment includes emerging and less common delivery methods such as transdermal patches, inhalable insulin, and implantable devices. While currently holding only about 5% of the market, this area is seeing rising interest due to innovations aimed at improving convenience and patient adherence.

Antidiabetics Market, Segmentation by Geography

In this report, the Antidiabetics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Antidiabetics Market Share (%), by Geographical Region

North America
North America leads the global antidiabetics market, contributing approximately 37% of the overall share. High diabetes prevalence, coupled with advanced healthcare infrastructure and early adoption of innovative therapies, drives this dominance. Strong reimbursement policies and presence of major market players also fuel growth.

Europe
Europe holds around 26% of the antidiabetics market, driven by increasing awareness, robust screening programs, and the widespread adoption of oral antidiabetic drugs. Countries like Germany, the UK, and France lead in consumption, supported by aging populations and strong regulatory support.

Asia Pacific
Asia Pacific is the fastest-growing region in the antidiabetics market, currently holding about 22% share. Rising rates of type 2 diabetes, urbanization, and lifestyle changes, particularly in India and China, are fueling market growth. Government initiatives and growing access to affordable treatment are also boosting adoption.

Middle East and Africa
Middle East and Africa together account for roughly 8% of the global market. While access to healthcare remains uneven, rising awareness and increasing rates of obesity-related diabetes are expanding the market. Investments in healthcare infrastructure are expected to support future growth.

Latin America
Latin America represents approximately 7% of the antidiabetics market. Countries such as Brazil and Mexico are witnessing a rise in diabetes prevalence, supported by improving healthcare access and expanding public health campaigns. The region is showing growing interest in oral therapies and insulin analogs.

This report provides an in depth analysis of various factors that impact the dynamics of Global Antidiabetics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Antidiabetics Market include:

• AstraZeneca
• Bayer Corporation
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly
• Halozyme Therapeutics
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk
• Oramed Pharmaceuticals Inc.
• Pfizer
• Sanofi
• Takeda Pharmaceutical.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis